The invention refers to
medicine, in particular to hepatology and
virology, and can be used for treatment, including complete
recovery, of patients with
viral hepatitis C, including its chronic form. This invention provides a remedy for treating
viral hepatitis C, that is, apoprotein
lactoferrin in a monomeric form. This invention also refers to a pharmaceutical composition for treating
viral hepatitis C that contains a therapeutically effective amount of apoprotein
lactoferrin in a monomeric form and a pharmaceutically acceptable vehicle, filler or
excipient. This invention also refers to a pharmaceutical composition for treating viral
hepatitis C that includes administration of apoprotein
lactoferrin in a monomeric form and to using apoprotein lactoferrin in a monomeric form for manufacturing a medication for treating viral
hepatitis C. The treatment method of this invention allows to prevent
virus viremia completely as a result of two or three weeks treatment, to prevent destruction of hepatocytes, affected with
hepatitis C
virus, together with the emission of additional number of viruses to the
blood circulation system and to end the existence of the affected with
virus hepatocytes with
apoptosis, thus, preventing the development of hepatosis,
cirrhosis and oncological damage to the liver, being the
terminal stage of the main
disease development.